Contact Us

Why a Partial CIDP Panel Is Not Enough: The Case for Comprehensive Nodopathy Testing

Table of Contents

Share Article

Autoimmune Neurology Series

India’s only validated 7-marker panel for CIDP, nodopathy, and paranodopathy – and why cutting corners costs patients the correct diagnosis.

ZX

ZeiniX Life Sciences | Autoimmune Neurology Diagnostics | India

Expert Perspective

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is not a single disease. It is a spectrum – one that includes classic CIDP, nodopathies, paranodopathies, and phenotypic variants that respond very differently to treatment. Yet today, a troubling trend is emerging across Indian diagnostic laboratories: the commercialisation of incomplete, unvalidated antibody panels that test for only four markers and market themselves as a “CIDP screen.”
This article lays out, clearly and on the basis of our own validated laboratory data from over 3,000 Indian patients, why this approach is scientifically inadequate, clinically misleading, and potentially harmful to patients who deserve an accurate diagnosis.

A diagnostic panel that does not cover the full antigenic spectrum is not a screen – it is a sieve with holes large enough for the most important diagnoses to fall through.

The ZeiniX 7-Marker Panel: India's First and Only Validated Comprehensive Screen

ZeiniX introduced and validated India’s only comprehensive antibody panel for CIDP, nodopathy, and paranodopathy. This panel was not assembled by sourcing commercially available reagents – it was built from the ground up, supported by years of focused research in autoimmune neurology, and validated against a repository of positive controls that no other laboratory in India possesses.

The panel comprises seven carefully selected markers, each targeting a distinct antigen at or near the node of Ranvier or the paranodal region:

NF140

Neurofascin isoform

Highest positivity in Indian patients

NF155

Paranodal neurofascin

Classic paranodopathy marker

NF186

Nodal neurofascin

Nodopathy spectrum

Contactin-1

Paranodal adhesion

Distinct treatment profile

Caspr1

Contactin-associated

Nodo-paranodopathy

Sulphatide

Sulfated glycolipid

Relapsing GBS / CIDP overlap

MAG

Myelin-associated glycoprotein

Distal demyelinating neuropathy

3,000+

Indian patients tested with this panel in the last 12 months alone

7

Markers covering the full nodal, paranodal, and myelin antigenic spectrum

Only

Laboratory in India with validated positive controls for all seven markers

What the Indian Patient Data Actually Shows

Perhaps the most striking finding from our dataset – and one that has significant implications for how this condition is screened in India – is the positivity distribution across markers. What we see in Indian patients does not mirror the Western literature.
Highest
NF140
High
Sulphatide
Moderate
NF186
Moderate
Contactin-1
Moderate
MAG
Lower
Caspr1
Lowest
NF155

Relative positivity based on ZeiniX lab data from >3,000 Indian patients. Bars represent relative proportion, not absolute percentages, which remain proprietary.

Critical finding

NF155 – the marker most prominently featured in Western literature and the one most likely to be included in a minimal commercial panel – is the least frequently positive marker in our Indian patient cohort. A panel anchored around NF155 will miss the majority of seropositive cases in the Indian population.

This is not a peripheral observation. It reflects a population-level biological difference that has begun to emerge in recent Asian literature. Our data precedes and corroborates these findings with a sample size that no other Indian centre can match. NF140, by contrast, is the single most informative marker in Indian patients – and it is absent from every competing four-marker panel currently being commercialised.

The 4-Marker Panel Problem: What Gets Missed

Several routine diagnostic laboratories – without any specialisation in autoimmune neurology – have begun offering panels comprising NF155, NF186, Contactin-1, and Caspr1, sourced from imported reagent kits and marketed as a CIDP screen. The appeal is economic: these panels are cheaper and the reagents are commercially available.

But the practice carries serious diagnostic and scientific risks.

The three missing markers are not trivial omissions. Each identifies a clinically distinct and therapeutically relevant patient subgroup.

Nf140: The Most Missed Marker in India

NF140 is a nodal isoform of neurofascin. It is expressed at the node of Ranvier and plays a critical structural role in saltatory conduction. Anti-NF140 antibody-positive patients represent a nodopathy subtype – not classic CIDP – and may not respond to standard intravenous immunoglobulin (IVIg) therapy in the same way. Missing this marker means not only a missed diagnosis, but potentially a failed therapeutic trial. Based on our data, NF140 is the single most commonly positive marker in Indian patients with autoimmune neuropathy. Any panel that omits it is, by definition, inadequate for the Indian population.

Sulphatide: The GBS-CIDP Bridge

Anti-sulphatide antibodies occupy a unique diagnostic niche. In our Indian patient cohort, we consistently identify sulphatide positivity in patients presenting with recurrent or relapsing Guillain-Barré Syndrome (GBS) – patients who are often misclassified as atypical CIDP or inadequately treated because their underlying antibody-mediated pathology is not identified. Sulphatide-associated neuropathy has distinct electrophysiological and clinical features, and its identification directly impacts management decisions. A panel that excludes sulphatide will fail this patient population entirely.

Mag: Distal Demyelinating Neuropathy with Unique Features

Anti-MAG (myelin-associated glycoprotein) neuropathy presents as a slowly progressive, predominantly sensory, distal demyelinating neuropathy – often in older patients with an IgM paraprotein. It is phenotypically and pathologically distinct from CIDP, though it frequently enters the CIDP differential diagnosis. Anti-MAG neuropathy has specific treatment implications, including the use of Rituximab, and standard IVIg may provide only partial or transient benefit. Without MAG testing, these patients may spend years on suboptimal therapy.

Perhaps most concerning about the proliferation of minimal commercial panels is the absence of any validation process. Validation of an antibody assay is not a bureaucratic formality. It requires, at minimum, the availability of genuine positive controls – confirmed seropositive patient samples – to verify that the assay can detect true positives at clinically relevant titres with acceptable sensitivity and specificity.

Validation: A Prerequisite That Cannot Be Shortcut

Perhaps most concerning about the proliferation of minimal commercial panels is the absence of any validation process. Validation of an antibody assay is not a bureaucratic formality. It requires, at minimum, the availability of genuine positive controls – confirmed seropositive patient samples – to verify that the assay can detect true positives at clinically relevant titres with acceptable sensitivity and specificity.
ZeiniX is, to our knowledge, the only laboratory in India that holds validated positive controls for all seven markers in this panel. Without positive controls, an assay cannot be validated. Without validation, a result – positive or negative – is scientifically uninterpretable.”
Laboratories launching reagent-imported panels without access to positive controls are not performing diagnostic tests – they are performing unvalidated experiments on clinical samples. A false negative from an unvalidated assay denies a patient a diagnosis. A false positive initiates unnecessary, potentially harmful immunosuppressive treatment. Either outcome is unacceptable in clinical medicine.
Our validation was built on a foundation of over 3,000 samples tested in the last year alone, with continuous quality review, internal controls, and cross-validation with clinical phenotypes. This is what meaningful diagnostic validation looks like.

The Asian Patient: Not a Subset of the Western Literature

The initial characterisation of anti-neurofascin and anti-contactin antibodies was largely conducted in European patient cohorts. For years, NF155 was described as the dominant nodal/paranodal antibody, and clinical guidelines in Western settings appropriately reflected this. However, emerging publications from East Asian and South Asian populations are beginning to demonstrate that the antibody prevalence landscape differs significantly in non-Caucasian patients.

Our Indian data aligns with and extends this emerging understanding. NF140 predominance, robust sulphatide positivity in GBS-CIDP overlap presentations, and comparatively lower NF155 frequencies are consistent with the possibility of genuine population-level antigenic differences in how autoimmune neuropathy manifests across ethnicities.
Importing a diagnostic paradigm designed for a Western population and applying it unchanged to Indian patients – particularly when the panel has been further truncated to only four markers – is not evidence-based medicine. It is diagnostic shortcutting at the patient’s expense.

What Clinicians and Patients Should Ask

When a CIDP antibody panel report lands on a neurologist’s desk, the right questions are not just about the results – they are about the test itself.

Questions Every Ordering Clinician Should Ask

  • Does the panel include NF140 - the most frequently positive marker in Indian patients?
  • Does it include Sulphatide, for relapsing/recurrent GBS presentations that may represent CIDP overlap?
  • Does it include MAG, to differentiate anti-MAG neuropathy from CIDP in the context of IgM paraproteinaemia?
  • Has the laboratory demonstrated validation against confirmed positive controls for each marker - not just for the four markers available commercially, but for all markers in the panel?
  • Does the laboratory have focused expertise in autoimmune neurology, or is this a general biochemistry or immunology laboratory that has added a neuropathy panel to its menu?

A panel that cannot answer yes to each of these questions is not a comprehensive CIDP screen. It is an incomplete, unvalidated test being sold as one.

Conclusion: Comprehensive Testing Is Not a Premium - It Is the Standard

ZeiniX introduced the 7-marker CIDP and nodopathy panel not because it was commercially convenient, but because the science demanded it and our patients deserved it. The extensive validation effort, the proprietary positive control library, and the Indian-population-specific data we have generated over years of focused research represent a standard of diagnostic quality that should not be undercut by cost-minimising imitations.
Autoimmune neuropathies are treatable. But treatment can only be correctly directed if the underlying antibody is correctly identified. A patient with anti-NF140 nodopathy who is seronegative on a four-marker panel does not receive a wrong diagnosis – they receive no diagnosis. A patient with sulphatide-associated relapsing neuropathy who is tested without that marker remains undiagnosed and unprotected. A patient with anti-MAG neuropathy who is given IVIg without Rituximab may improve partially and temporarily, then relapse – without ever understanding why.

Autoimmune neuropathies are treatable. But treatment can only be correctly directed if the underlying antibody is correctly identified. A patient with anti-NF140 nodopathy who is seronegative on a four-marker panel does not receive a wrong diagnosis – they receive no diagnosis. A patient with sulphatide-associated relapsing neuropathy who is tested without that marker remains undiagnosed and unprotected. A patient with anti-MAG neuropathy who is given IVIg without Rituximab may improve partially and temporarily, then relapse – without ever understanding why.

The cost difference between a four-marker and a seven-marker panel is negligible against the cost – financial and human – of a missed or delayed diagnosis in an autoimmune neuropathy patient. Comprehensive testing is not a premium service. It is the minimum standard that evidence-based autoimmune neurology demands.

References

  1. ZeiniX Life Sciences is India’s dedicated autoimmune neurology diagnostics laboratory.
  2. The 7-marker CIDP/Nodopathy/Paranodopathy panel – comprising NF140, NF155, NF186, Contactin-1, Caspr1, Sulphatide, and MAG – is offered exclusively by ZeiniX, validated against confirmed Indian patient positive controls.
  3. For clinical queries and referrals, contact your ZeiniX representative.
  4. Data on file; references to published Asian population studies available on request.
Scroll to Top